trial

Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)

NCTId NCT00517075
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 14 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2011-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
14 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2004-09
Primary completion
2011-06
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Transcranial Magnetic Stimulation (TMS)repetitive Transcranial Magnetic Stimulation

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
Arielle D. Stanford, MDPrincipal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimu — primary completion2011-06

Facts & assertions

4 sourced
Enrollment
14
Phase
PHASE2
Primary Completion Date
2011-06
Status
TERMINATED
relationships
The graph out of here
drug
Transcranial Magnetic Stimulation (TMS)
drug
repetitive Transcranial Magnetic Stimulation
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
National Institute of Mental Health (NIMH)
company
National Alliance for Research on Schizophrenia and Depression
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Arielle D. Stanford, MD
person